Search
forLearn
5 / 801 resultslearn Sodium PCA
learn sh-Polypeptide-7
learn pyrrolidone carboxylic acid
learn copper tripeptide-1
Research
5 / 499 resultsresearch The postnatal offspring of finasteride-treated male rats show altered ERα and PCNA expression in the liver
Finasteride use in male rats may harm their male offspring's liver function.
research An Extended Epidermal Response Heals Cutaneous Wounds in the Absence of a Hair Follicle Stem Cell Contribution
Skin can heal wounds without hair follicle stem cells, but it takes a bit longer.
research Maintenance of high proliferation and multipotent potential of human hair follicle-derived mesenchymal stem cells by growth factors
Growth factors help hair follicle stem cells grow and stay versatile.
research The Success of Thread-embedding Therapy in Generating Hair Re-growth in Mice Points to Its Possibly Having a Similar Effect in Humans
Thread-embedding therapy helped hair grow back in mice and might do the same in humans.
research Effects of Lespedeza Cuneata aqueous extract on testosterone-induced prostatic hyperplasia
Lespedeza cuneata extract may help treat enlarged prostate.
Community Join
5 / 1000+ resultscommunity Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
community Currently participating in the Extended Phase III clinical trial of Pyrilutamid in China
A user from China is participating in a clinical trial for Pyrilutamid, a potential hair loss treatment originally developed for prostate cancer. They've experienced no side effects except initial scalp itchiness, and will share results after the year-long trial.
community A warning to anyone considering 3rd party sourcing PP405 or its analogs
Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.
community Pp405 phase 2a clinical results
PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.
community is there any news about pp405 please
There is no new information on pp405, with data collection expected to finish by the end of 2025. Users are discussing the timeline for data analysis and completion of Pelage Pharmaceuticals' phase 2 study.